A Phase 2 Extension Study of Study GCS-100-CS-4002
Latest Information Update: 14 Jan 2020
Price :
$35 *
At a glance
- Drugs GCS 100 (Primary)
- Indications Renal failure
- Focus Adverse reactions
- Sponsors La Jolla Pharmaceutical Company
- 22 Dec 2016 Status changed from active, no longer recruiting to completed.
- 01 Sep 2015 Planned End Date changed from 1 Jan 2016 to 1 Dec 2016 as per ClinicalTrials.gov record.
- 01 Sep 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Jun 2016 as per ClinicalTrials.gov record.